Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at $19,221,046.28. The trade was a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $122.27, for a total transaction of $2,445,400.00.
• On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRM traded down $0.47 during midday trading on Tuesday, hitting $98.23. The company’s stock had a trading volume of 579,012 shares, compared to its average volume of 897,826. The stock has a market capitalization of $6.38 billion, a price-to-earnings ratio of -6.75 and a beta of 0.52. The stock’s 50 day simple moving average is $110.38 and its 200 day simple moving average is $101.91. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The company’s revenue for the quarter was up 37.9% on a year-over-year basis. As a group, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -4.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of research reports. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. TD Cowen lowered their price target on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Robert W. Baird set a $123.00 price objective on Mirum Pharmaceuticals in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.33.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently modified their holdings of MIRM. BlackRock Inc. acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $513,945,000. Janus Henderson Group PLC grew its position in Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the period. State Street Corp grew its position in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after acquiring an additional 797,088 shares during the period. Wellington Management Group LLP raised its stake in Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after acquiring an additional 672,118 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Mirum Pharmaceuticals during the second quarter worth $78,434,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.